

Claims

1. A combination composition for the prevention and treatment of kidney dysfunctions and diseases consisting essentially of:
a) acetyl L-carnitine or a pharmacologically acceptable salt thereof;
and
b) propionyl L-carnitine or a pharmacologically acceptable salt thereof,
wherein the weight ratio of acetyl L-carnitine to propionyl L-carnitine is from 1:1 to 1:10.
2. The composition of claim 1 wherein the pharmacologically acceptable salt is selected from the group comprising: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane sulphonate.
3. The composition of any of the preceding claims, which further comprises vitamins, coenzymes, mineral substances and antioxidants.
4. The composition of claims 1-3, in the form of tablets, lozenges, pills, capsules, granulates, syrups, vials or drops.
5. A method for the prevention and/or treatment of kidney dysfunctions or diseases which comprises administering to an individual in need thereof 2-5 mg of acetyl L-carnitine and 2-5 mg of propionyl L-carnitine/kg body weight/day or an equimolar amount of a pharmacologically acceptable salt thereof.
6. Use of acetyl L-carnitine or a pharmacologically acceptable salt thereof in admixture with propionyl L-carnitine or a pharmacologically acceptable salt thereof for preparing a combination composition wherein the weight-ratio of acetyl L-carnitine to propionyl L-carnitine

is from 1:1 to 1:10, for the prevention and treatment of kidney dysfunctions and nephropathies.

7. The use of claim 6, wherein the nephropathies are brought about by nephrotoxic drugs or environmental contaminants.

8. The use of claim 7, wherein the nephrotoxic drugs comprise lithium, antibiotics and anticancer drugs and the environmental contaminants comprise ochratoxin.